bilateral adrenalectomy ( Ritzel et al. 2013 , Pivonello et al. 2015 , Tritos & Biller 2018 , Feelders et al. 2019 ). The somatostatin analogue pasireotide is the only pituitary-targeting pharmaceutical that is approved for the treatment of
Search Results
Adriana Albani, Luis Gustavo Perez-Rivas, Sicheng Tang, Julia Simon, Kristin Elisabeth Lucia, Paula Colón-Bolea, Jochen Schopohl, Sigrun Roeber, Michael Buchfelder, Roman Rotermund, Jörg Flitsch, Jun Thorsteinsdottir, Jochen Herms, Günter Stalla, Martin Reincke, and Marily Theodoropoulou
Thomas Cuny, Caroline Zeiller, Martin Bidlingmaier, Céline Défilles, Catherine Roche, Marie-Pierre Blanchard, Marily Theodoropoulou, Thomas Graillon, Morgane Pertuit, Dominique Figarella-Branger, Alain Enjalbert, Thierry Brue, and Anne Barlier
( Iwama et al. 2014 ). In light of the so-called Nelson’s syndrome secondary to bilateral adrenalectomy and abolition of the cortisol-induced negative feedback, the issue concerning the role of PEG in promoting growth of a residual GH-secreting tumor
Anna Angelousi, Aimee R Hayes, Eleftherios Chatzellis, Gregory A Kaltsas, and Ashley B Grossman
/or metyrapone. Surgical intervention with bilateral adrenalectomy is another option available to some patients ( Hayes & Grossman 2018 ). However, systemic therapy with tyrosine kinase inhibitors such as vandetanib offers a further management strategy for
